Pharmacotherapy for erectile dysfunction.
- Author:
Wan-Li HU
1
;
Li-Quan HU
Author Information
1. Research Center of Urology and Andrology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Apomorphine;
pharmacology;
therapeutic use;
Erectile Dysfunction;
drug therapy;
Humans;
Male;
Phosphodiesterase Inhibitors;
pharmacology;
therapeutic use;
Piperazines;
pharmacology;
therapeutic use;
Purines;
pharmacology;
therapeutic use;
Rats;
Sildenafil Citrate;
Sulfones;
pharmacology;
therapeutic use;
Yohimbine;
pharmacology;
therapeutic use
- From:
National Journal of Andrology
2005;11(8):626-630
- CountryChina
- Language:Chinese
-
Abstract:
In the recent few years, especially since the introduction of phosphodiesterase-5 inhibitor, sildenafil, most researchers have focused their researches on biochemistry and physiology of erectile function. New progress has been made made in basic and clinic researches on pharmacotherapy for ED. In this article, the putative molecular or cellular mechanism of actions of the available centrally and peripherally acting drugs are reviewed, providing details about the current and most explosive area of drug research and development in erectile dysfunction.
